Innoviva (INVA) director Josephine Linden files Form 3 showing no share ownership
Innoviva, Inc. director Josephine Linden has filed a Form 3, an initial statement of beneficial ownership, indicating she holds no securities in the company. The filing, dated May 18, 2026, reports zero shares beneficially owned. This type of filing establishes a baseline for an insider's ownership and does not reflect any buying or selling activity.
Innoviva (INVA) director receives RSU and stock option grants as board compensation
Innoviva, Inc. director Linden Josephine received equity compensation awards, including 9,461 shares of common stock, 5,733 restricted stock units, and non-statutory stock options for 9,166 shares with an exercise price of $21.80. These grants, made upon her appointment to the Board on May 18, 2026, are subject to vesting schedules tied to continued service and certain acceleration events. This report details the compensation structure rather than open-market transactions.
Innoviva Appoints Josephine Linden to Strengthen Board Oversight
Innoviva announced that two directors, Derek Small and Mark DiPaolo, resigned to focus on Syndeio BioSciences, an investment of Innoviva in neuropsychiatric therapies. In response, Innoviva appointed Josephine Linden, a former Goldman Sachs partner, as an independent director to its audit committee. This move aims to enhance financial oversight and governance, with Linden receiving restricted stock units and stock options.
Innoviva (INVA) refreshes board as two directors resign, adds Josephine Linden
Innoviva, Inc. announced changes to its Board of Directors, with Derek Small and Mark DiPaolo resigning on May 12, 2026, to focus on Syndeio BioSciences. Josephine Linden, an experienced investment management expert and former Goldman Sachs partner, was elected to the board on May 18, 2026, and is expected to join the Audit Committee. She will receive RSU awards and stock options as part of her compensation, with independent director status confirmed by the board.
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals announced its first quarter 2026 financial results, highlighting its primary focus on advancing AP-SA02, a Staphylococcus aureus therapeutic phage candidate, into a Phase 3 study. The company secured a $25 million credit agreement with Innoviva, received Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA for AP-SA02, and appointed Dr. Daniel Gilmer to its Board of Directors to bring commercial expertise. The net loss for Q1 2026 was $115.3 million, with cash and cash equivalents at $4.8 million.
Armata Pharmaceuticals, Inc. Enters into A Secured Credit Agreement with Innoviva Strategic Opportunities Llc
Armata Pharmaceuticals, Inc. has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a subsidiary of its largest shareholder, Innoviva, Inc. The agreement provides Armata with a $25.0 million loan that will mature on January 11, 2029. This financial arrangement helps secure funding for the clinical-stage biotechnology company as it continues to develop bacteriophage therapeutics for difficult-to-treat bacterial infections.
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Innoviva Inc. has reported its second-quarter 2023 financial results, highlighting recent company progress. This report was originally published as a press release and disseminated via Quantisnow, a platform providing real-time market data to retail investors.
What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders
Innoviva (INVA) reported a significant profit rebound in Q1 2026 with US$186.6 million in net income, following a prior year loss. Concurrently, the company filed a US$207.99 million shelf registration for an employee stock ownership plan, signaling management's focus on employee alignment. These events highlight Innoviva's shift to a royalty-driven, cash-generative model, though they also raise questions about potential future share dilution and the sustainability of profits.
Innoviva (INVA) Q1 Profit Swing Challenges Bearish Earnings Decline Narratives
Innoviva (INVA) reported a significant profit swing in Q1 2026, with basic EPS moving from a loss of US$0.74 to a profit of US$2.52, challenging narratives of earnings decline. While bulls point to a low P/E ratio and a high DCF fair value, bears caution about forecast earnings declines of 22.2% per year, shareholder dilution, and a high proportion of non-cash earnings in reported profits. The article highlights both optimistic and skeptical viewpoints regarding Innoviva's financial health and future prospects.
INVA SEC Filings - Innoviva 10-K, 10-Q, 8-K Forms
This page provides access to Innoviva (INVA) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-powered summaries. It details Innoviva's business as a diversified healthcare holding company with a royalties portfolio and a critical care/infectious disease platform. Recent filings highlighted include an insider stock disposition, a Schedule 13G/A from Renaissance Technologies, and a 13G/A from Franklin Resources.
Innoviva (INVA) CEO receives new RSU and stock option grants
Innoviva, Inc. has conditionally granted its CEO, Pavel Raifeld, 126,646 time-vested restricted stock units (RSUs) and 312,500 non-statutory stock options with an exercise price of $22.99. These equity awards are part of his compensation, subject to stockholder approval of the 2026 Equity Incentive Plan on May 4, 2026. The awards will vest over time, with 25% vesting on February 20, 2027, and the remainder vesting in quarterly installments, with accelerated vesting provisions under certain change-in-control scenarios.
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. announced strong financial results for the first quarter of 2026, driven by resilient royalty revenue and excellent commercial progress from Innoviva Specialty Therapeutics (IST). The company reported $98.0 million in total revenue, a 37% growth in net product sales for IST, and $186.6 million in net income, largely due to appreciation in strategic investments like Armata Pharmaceuticals. Innoviva also highlighted significant capital allocation activity, including share repurchases, and noted the FDA approval of NUZOLVENCE® in late 2025.
Innoviva (INVA) awards RSUs and stock options to accounting chief
Innoviva, Inc. has awarded its Chief Accounting Officer, Marianne Zhen, 12,766 time-vested restricted stock units and 31,500 non-statutory stock options with an exercise price of $22.99 per share. These awards are conditional on stockholder approval of the company's 2026 Equity Incentive Plan on May 4, 2026. The vesting schedule involves 25% vesting on February 20, 2027, with the remainder vesting quarterly thereafter, subject to continuous service and specific change-in-control or involuntary termination provisions.
Innoviva (NASDAQ: INVA) director gets RSUs and 10,000 stock options at $22.99
Innoviva, Inc. director Mark DiPaolo received new equity awards, including 9,786 restricted stock units (RSUs) and 10,000 non-statutory stock options with an exercise price of $22.99 per share. These awards, granted under the company's 2026 Equity Incentive Plan, will vest with continuous service and include accelerated vesting clauses. The transactions were reported in a Form 4 SEC filing, increasing his direct common stock holdings to 140,492 shares.
[Form 4] Innoviva, Inc. Insider Trading Activity
Innoviva, Inc. Chief Financial Officer, Stephen Basso, received conditional equity-based compensation awards, including 37,994 time-vested restricted stock units (RSUs) and 93,750 non-statutory stock options. These awards are contingent on stockholder approval of the company's 2026 Equity Incentive Plan on May 4, 2026. Following the RSU grant, Basso directly holds 88,007 shares of Innoviva common stock, with vesting schedules tied to continued service and potential acceleration events.
Earnings Flash (INVA) Innoviva, Inc. Reports Q1 Revenue $98.0M, vs. FactSet Est of $101.6M
Innoviva, Inc. (INVA) announced its Q1 2026 revenue was $98.0 million, falling short of the FactSet estimate of $101.6 million. The company is a diversified holding company with a focus on healthcare royalties and assets, including respiratory treatments partnered with Glaxo Group Limited (GSK), and other approved products like GIAPREZA, XERAVA, and XACDURO. Innoviva also has zoliflodacin, an investigational gonorrhea treatment, in Phase III clinical trials.
[8-K] Innoviva, Inc. Reports Material Event
Innoviva, Inc. reported a highly profitable first quarter of 2026, driven by significant gains in fair values of equity method investments totaling $191.2 million, alongside robust royalty and product sales. The company achieved a net income of $186.6 million, a substantial turnaround from a net loss in the prior year, and saw a 37% year-over-year growth in Innoviva Specialty Therapeutics net product sales. Innoviva also highlighted its strong cash position of $603.1 million and continued share repurchase activities, demonstrating financial flexibility and confidence in its long-term value.
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. reported strong first-quarter 2026 financial results, driven by resilient royalty revenue and significant growth in net product sales from Innoviva Specialty Therapeutics (IST). The company generated $98.0 million in total revenue and achieved $34.2 million in U.S. net product sales for IST, representing 29% year-over-year growth. Innoviva also highlighted meaningful value creation from its strategic healthcare assets and active capital allocation through its share repurchase program.
Innoviva: Q1 Earnings Snapshot
Innoviva Inc. (INVA) reported a net income of $186.6 million for its first quarter, amounting to $2.22 profit per share. Adjusted earnings were 44 cents per share, and the biopharmaceutical company generated $98 million in revenue during the period. This financial summary was generated using data from Zacks Investment Research.
Innoviva (Nasdaq:INVA) - Stock Analysis
This article provides a detailed stock analysis of Innoviva (Nasdaq: INVA), a biopharmaceutical company. It covers the company's valuation, future growth prospects, past performance, financial health, dividend, management, and ownership, alongside recent news and analyst updates. The analysis highlights risks such as high non-cash earnings and forecasted earnings decline, while also noting the company becoming profitable this year and trading below fair value.
Innoviva Shareholders Back Directors, Pay Plan and Incentives
Innoviva shareholders re-elected five directors, approved the executive compensation program, ratified Deloitte & Touche LLP as the independent auditor, and endorsed the 2026 Equity Incentive Plan at their annual meeting. These decisions signal broad support for the company's current governance and compensation strategies. Analysts have a positive outlook on INVA stock, with a Buy rating and a $32.00 price target.
Innoviva (NASDAQ: INVA) holders approve board, pay and 2026 equity plan
Innoviva, Inc. stockholders approved several key proposals at their Annual Meeting on May 4, 2026. These included the election of five directors, led by CEO Pavel Raifeld, for one-year terms, the non-binding advisory approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, shareholders approved Innoviva's 2026 Equity Incentive Plan.
Jennison Associates LLC Buys New Shares in Innoviva, Inc. $INVA
Jennison Associates LLC initiated a new position in Innoviva, Inc. (NASDAQ:INVA) during the fourth quarter, acquiring 46,403 shares valued at approximately $928,000. This move contributes to Innoviva's high institutional ownership of around 99.12%, with other major institutional investors like Vanguard and Arrowstreet Capital also increasing their stakes. Innoviva recently exceeded analyst expectations with strong quarterly earnings and revenue, and the stock maintains a "Moderate Buy" consensus rating with a price target of $34.80.
Technical Reactions to INVA Trends in Macro Strategies
Innoviva Inc. (NASDAQ: INVA) is showing weak near and mid-term sentiment despite a long-term positive outlook. AI models have generated three distinct trading strategies with a notable 36.0:1 risk-reward setup targeting a 9.7% gain against 0.3% risk. The analysis indicates various support and resistance levels across different time horizons, with a strong signal for the long term.
INVA SEC Filings - Innoviva 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Innoviva (INVA) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. Each filing is accompanied by AI-powered summaries to highlight key information for investors and traders. Recent filings include details on ownership stakes by Dimensional Fund Advisors and Bank of Nova Scotia, insider transactions by the CFO and CAO, and Innoviva's strong Q3 2025 financial results.
INVA SEC Filings - Innoviva 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Innoviva (INVA) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading documents. It highlights Innoviva's business as a diversified healthcare holding company and explains how these filings detail its royalty revenues, product sales, and investment performance. The platform also offers AI-powered summaries and real-time updates for easy access and analysis of regulatory disclosures.
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Innoviva, Inc. $INVA
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 49.9% in Q4, now holding 173,119 shares valued at $3.46 million. Innoviva reported strong quarterly earnings, beating analyst expectations with an EPS of $1.94 and revenue of $114.61 million, demonstrating a robust net margin of 65.92%. Institutional investors own a substantial 99.12% of the stock, and analysts maintain a "Moderate Buy" rating with a consensus target price of $34.80.
[SCHEDULE 13G] Innoviva, Inc. Passive Investment Disclosure (>5%)
Vanguard Portfolio Management has filed a Schedule 13G for Innoviva Inc (INVA), reporting beneficial ownership of 4,288,063 shares of common stock, which represents 5.79% of the class. This filing indicates that Vanguard holds sole voting power over 63,112 shares and sole dispositive power over all 4,288,063 shares. The disclosure was signed by Ashley Grim, Head of Global Fund Administration, on April 29, 2026.
Innoviva (INVA) to Release Quarterly Earnings on Wednesday
Innoviva (NASDAQ:INVA) is scheduled to release its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts projecting earnings of $0.43 per share and revenue of $101.565 million. The company reported strong Q4 results, significantly exceeding expectations. Shares currently trade with a market cap of $1.75 billion and a P/E of 7.77, holding an average analyst rating of "Moderate Buy" with a $34.80 price target.
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Innoviva, Inc. (NASDAQ:INVA) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $34.80. The biopharmaceutical company recently reported strong earnings, with $1.94 EPS against a $0.34 consensus and revenue of $114.6 million, significantly beating analyst estimates. Innoviva maintains a strong financial position with substantial institutional ownership and healthy liquidity ratios.
Innoviva (NASDAQ:INVA) Shares Cross Above 200-Day Moving Average - Time to Sell?
Innoviva (NASDAQ:INVA) stock has surpassed its 200-day moving average, trading at $23.92 with increased volume, indicating a positive technical trend. Analysts have a consensus "Moderate Buy" rating with an average target price of $34.80. The company reported strong financial results, including significant quarterly earnings beat and robust margins, suggesting solid fundamentals.
INVA Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Innoviva Inc. (INVA), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. It details momentum indicators like MACD and RSI, support and resistance levels, and Innoviva's performance relative to its 200-day moving average, which suggests a long-term bullish trend.
Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating and a $32.00 price target for Innoviva Inc. (NASDAQ:INVA), citing the company's strong recurring royalty business, which generated $250 million in 2025, as a source of stability. Innoviva's financial health is further supported by a 75% gross profit margin and a 14.64 current ratio, and the stock is considered undervalued with a P/E ratio of 7.05. The company is actively investing royalty revenue into its Specialty Therapeutics segment and holds a significant stake in Armata Pharmaceuticals.
(INVA) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily analyzes Innoviva Inc. (NASDAQ: INVA), highlighting strong sentiment across all horizons and an exceptional risk-reward short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis indicating strong support and resistance levels for the stock.
Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $32
Cantor Fitzgerald has reiterated its Buy rating for Innoviva (INVA.US) and maintained its target price at $32. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Cantor Fitzgerald reiterates Innoviva stock rating on royalty strength
Cantor Fitzgerald has reiterated an Overweight rating and $32.00 price target for Innoviva Inc. (NASDAQ:INVA), highlighting the company's strong foundational stability driven by its recurring royalty business, which generated approximately $250 million in 2025. The firm noted Innoviva's impressive financial health with a 75% gross profit margin and a 14.64 current ratio, along with aggressive capital redeployment into its Innoviva Specialty Therapeutics segment and strategic investments. BTIG also initiated coverage with a Buy rating and a $35.00 price target, anticipating significant benefits from royalty rights for COPD and asthma therapies through 2030.
Innoviva Stock Crosses 200-Day Moving Average
Shares of Innoviva, Inc. (NASDAQ:INVA) have crossed above their 200-day moving average, indicating a potential bullish trend. This surge is attributed to positive analyst sentiment and the company's stable, royalty-focused business model in the biotech sector. Analysts maintain a 'Moderate Buy' rating with an average price target of $34.80, suggesting further upside potential for the stock.
INVA Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for INVA, detailing past quarterly results and future estimates. It highlights that analysts project Q1 2026 revenue of $100.31M and an EPS of $0.39, with recent estimates showing no change. The report also examines how INVA's stock price typically reacts to earnings announcements, noting a 0.99% change 10 days before and a 3.2% change 10 days after, suggesting potential buying opportunities based on long-term fundamentals.
Innoviva Inc (HVE.SG) Stock Price, News, Quote & History
This page provides comprehensive financial information for Innoviva Inc (HVE.SG), including its current stock price, recent news, quotes, and historical data. As of April 2, 2026, the stock was trading at 19.80 EUR, down 1.98%. The page also details performance metrics compared to the S&P 500, showing Innoviva's YTD return at +20.73% and 1-year return at +20.73%.
Innoviva, Inc. (INVA) stock price, news, quote and history
This article provides a comprehensive overview of Innoviva, Inc. (INVA), a biopharmaceutical company, including its stock price, historical data, and financial performance. It details the company's royalty portfolio of medicines, development pipeline, key financial metrics like market cap and P/E ratio, and analyst insights. The report also lists comparable companies in the biotechnology sector.
INVA Stock Price, Quote & Chart | INNOVIVA INC (NASDAQ:INVA)
This article provides a detailed overview of INNOVIVA INC (NASDAQ:INVA) stock, including its current price, performance metrics, and key statistics. It also highlights ChartMill's technical and fundamental ratings, recent earnings reports, analyst forecasts, and company profile. The stock is noted for its strong financial health, profitability, and inclusion in several "value" stock screens.
INVA PE Ratio & Valuation, Is INVA Overvalued
Innoviva Inc (INVA) is currently considered undervalued, with a forward PE ratio of 7.57 compared to its five-year average of 11.86. Its fair price is estimated between $35.41 and $65.32, significantly above its current price of $23.41, indicating it is undervalued by 33.89%. The company also shows a P/B ratio of 1.48 and a Forward FCF yield of 11.25%, with robust revenue growth contributing to a sustainable premium.
Working capital per share of Innoviva, Inc. – BX:HVE
This article provides financial information for Innoviva, Inc. (BX:HVE) on TradingView, specifically focusing on its working capital per share. It mentions the company's market status on BX Swiss and highlights available financial data.
Price-Driven Insight from (INVA) for Rule-Based Strategy
This article provides a price-driven insight for Innoviva Inc. (NASDAQ: INVA) for rule-based trading strategies, highlighting a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It presents specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward ratios. The analysis emphasizes AI-generated signals for entry and exit points, support, and resistance levels.
Book value per share of Innoviva, Inc. – BX:HVE
This article provides financial information for Innoviva, Inc. (BX:HVE), specifically focusing on its book value per share. It details the period, value, and percentage change of this metric, indicating that the market is currently closed.
Net current asset value per share of Innoviva, Inc. – BX:HVE
This page from TradingView provides financial information for Innoviva, Inc. (HVE BX Swiss), specifically focusing on its net current asset value per share. The content displays a table with "Period," "Value," "Change," and "Change %" for this metric.
INVA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Innoviva Inc.'s (INVA) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors HRMY and VCEL. INVA demonstrates strong profitability with a gross margin of 66.02%, an operating margin of 34.02%, and a net margin of 143.22%, alongside a 29.09% Return on Equity. The company, with a market capitalization of $1.68B, holds a leading position in its sector despite slightly lower gross margins compared to some rivals.
Innoviva (INVA) files 10-K/A adding Armata audited financials and new officer certifications
Innoviva, Inc. (INVA) filed an Amendment No. 1 to its 2025 Annual Report (Form 10-K/A) to incorporate audited financial statements for Armata Pharmaceuticals, Inc. and new certifications from its principal executive and financial officers. This amendment was made to comply with SEC Rule 3-09 of Regulation S-X, which requires separate financial reporting for significant equity investees. The filing explicitly states that all other disclosures in the original annual report remain unchanged, including Innoviva's previously reported financial results.
Vanguard discloses 0% Innoviva holding (NASDAQ: INVA)
Vanguard has filed an Amendment No. 10 to its Schedule 13G/A, reporting 0% beneficial ownership of Innoviva Inc. (NASDAQ: INVA) common stock. This change follows an internal realignment on January 12, 2026, where Vanguard and certain subsidiaries will now report beneficial ownership separately. The filing clarifies that Vanguard no longer holds, or is deemed to hold, beneficial ownership over these securities.
INNOVIVA PB Ratio: 1.44 — 30% Below Median
Innoviva Inc (INVA) has a Price-to-Book (PB) Ratio of 1.44 as of March 27, 2026, which is 30% below its 10-year median of 2.07. GuruFocus rates INVA with a GF Score of 88/100 and a GF Value of $19.31, indicating it is modestly overvalued, and notes 5 warning signs for investors. Despite its lower-than-median PB Ratio and strong industry ranking within biotechnology, GuruFocus's overall analysis suggests the stock is currently overvalued compared to its estimated fair value.
